Metabolic Complications

Resources for Families

Metabolic Assessment, Screening & Monitoring Tools

Metabolic Monitoring Learning Program
This course provides an overview of first-generation antipsychotic (FGA) and second-generation antipsychotic (SGA) use in BC and Canada as it relates to children and youth. The three modules include a review of current approvals and prescription trends, examine the implications of SGA use and review evidence-informed practices for the monitoring and management of SGAs.
Evidence-Based Recommendations for Monitoring Safety of Second Generation Antipsychotics in Children and Youth
Evidence-based recommendations for monitoring SGA safety are provided in the guideline.

First do no Harm: Promoting an Evidence-Based Approach to Atypical Antipsychotic use in Children and Adolescents
Journal article reviewing the evidence for efficacy and metabolic effects of atypical antipsychotics (AAPs), and to propose a metabolic monitoring protocol for AAP use in children and adolescents.

Increased Prevalence of Obesity and Glucose Intolerance in Youth Treated With Second-Generation Antipsychotic Medications
Journal article comparing the rates of obesity, impaired fasting glucose (IFG), and type 2 diabetes between second-generation antipsychotic (SGA)-treated and -naive youth.

Management Recommendations for Metabolic Complications Associated with Second Generation Antipsychotic Use in Children and Youth
Previous guidelines have been developed for monitoring for metabolic and neurological complications. This is a complementary set of treatment recommendations if abnormal measurements or results are encountered.

Treatment recommendations for extrapyramidal side effects associated with second generation anti-psychotic use in children and youth
Journal article providing guidance to clinicians on the clinical management of extrapyramidal side effects of second-generation antipsychotics